Critical Biologics Corporation Report issue

For profit Phase 2
Founded: Cambridge MA United States (2004)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2008
NCT00671307
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

rhu-pgelsolin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1